Editor's Note: I've been recommending biotech for the last year. Nothing BOOMS higher or faster than the biotech sector during a "Melt Up". But if you haven't seen huge gains in biotech yet, you need to seriously consider the message below. Dear Reader, Next month, trial results we've waited almost 4 years to receive could create the biggest story in the pharmaceutical world. Along the way, one small biotech stock could double your money. That's because the data concerns a treatment that has the potential to become the bestselling new drug in every U.S. pharmacy. Lipitor – the bestselling drug of all-time – has made $148 billion for Pfizer in its lifetime. But our top biotech expert says if this new treatment gains FDA approval, it could become an even bigger blockbuster drug. Yet today, the small firm who owns the patent is almost unknown. After watching this stock closely for nearly four years – including more than 50,000 miles of travel, and talking with brain surgeons up and down the West coast – our expert now believes this stock could make you a fortune if you get in today. That's why, this week only, we're offering the most generous guarantee I've ever seen us make. In short: If we're wrong – and the stock doesn't double in the next 18 months – we’ll give you $5,000 in credit toward any Stansberry product or service. Along the way, you'll receive 18 months of our most exclusive research service… PLUS the $5,000 credit we're offering you today, if we're wrong. Just keep in mind: We're limiting this opportunity to the first 500 readers who say "yes." After that, we're closing the doors on this offer, and you'll be too late. So don’t delay. Click here to get the full details. Regards, Justin Brill
Editor, The Digest P.S. Spots are already filling… So if you'd rather skip to the front of the line, simply give us a call before 4 p.m. (Eastern) today at (800) 439-5059. | 